AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30856236 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive BP reduction (target SBP <150 mmHg, n = 27)
Number of subjects: 71
Study 30856236 — intervention group
Group type: COMPARATOR
Intervention: Conservative BP reduction (target SBP <180 mmHg, n = 25)
Number of subjects: 71
Study 30856236 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SBP between aggressive and conservative groups
Number of subjects: 71
Study 30856236 — intervention group
Group type: COMPARATOR
Intervention: Comparison of mean rTmax between aggressive and conservative groups
Number of subjects: 71
Study 30316737 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Aerobic Training (CAT)
Number of subjects: 69
Study 30316737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Aerobic Training (IAT)
Number of subjects: 69
Study 30316737 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 69
Study 30316737 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CAT and IAT groups
Number of subjects: 69
Study 26861922 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message support for weight loss (adapted from DPP curriculum for 12 months)
Number of subjects: 163
Study 26861922 — intervention group
Group type: COMPARATOR
Intervention: Control group (invitation to DPP classes only)
Number of subjects: 163
Study 26861922 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message support for weight loss
Number of subjects: 163
Study 24180595 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIT + vitamin D (650 U/day)
Number of subjects: 50
Study 24180595 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIT alone
Number of subjects: 50
Study 24180595 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 50
Study 22706859 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing (Hybrid Capture 2 assay, Qiagen)
Number of subjects: 560
Study 22706859 — intervention group
Group type: COMPARATOR
Intervention: Repeat cytology
Number of subjects: 560
Study 22706859 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 560
Study 20444958 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified food product (total dose = 56 mg Fe/d), consumed twice daily during the 9-week BCT course.
Number of subjects: 0
Study 20444958 — intervention group
Group type: COMPARATOR
Intervention: Placebo, consumed twice daily during the 9-week BCT course.
Number of subjects: 0
Study 20444958 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-deficient anemic soldiers (subgroup of intervention group).
Number of subjects: 0
Study 18387338 — intervention group
Group type: EXPERIMENTAL
Intervention: SICI using PA-directed currents
Number of subjects: 29
Study 18387338 — intervention group
Group type: EXPERIMENTAL
Intervention: SICI using AP-directed currents
Number of subjects: 29
Study 15712083 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous therapy
Number of subjects: 74
Study 15712083 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 cell count-guided therapy
Number of subjects: 74
Study 15712083 — intervention group
Group type: EXPERIMENTAL
Intervention: Week-on/week-off (WOWO) therapy
Number of subjects: 74
Study 15712083 — intervention group
Group type: EXPERIMENTAL
Intervention: All therapy arms
Number of subjects: 74
Study 12001824 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% N-acetylcarnosine (NAC) solution, topical eyedrops twice daily
Number of subjects: 49
Study 12001824 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 49
Study 12001824 — intervention group
Group type: COMPARATOR
Intervention: No eyedrops
Number of subjects: 49
Study 10424185 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyester clothing with low moisture absorption and low air permeability (A)
Number of subjects: 3
Study 10424185 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyester clothing with low moisture absorption and high air permeability (B)
Number of subjects: 3
Study 10424185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton clothing with high moisture absorption and high air permeability (C)
Number of subjects: 3
Study 10424185 — intervention group
Group type: EXPERIMENTAL
Intervention: All three kinds of clothing
Number of subjects: 3
Study 7547617 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pancreatic enzyme supplements
Number of subjects: 23
Study 7547617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 2237719 — intervention group
Group type: EXPERIMENTAL
Intervention: Meciadanol, 500 mg every six hours through a nasogastric tube
Number of subjects: 298
Study 2237719 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate, 1,000 mg every six hours through a nasogastric tube
Number of subjects: 298
Study 2237719 — intervention group
Group type: COMPARATOR
Intervention: Antacid (Maalox), 15 ml every hour through a nasogastric tube
Number of subjects: 298
Study 31512330 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CRE)
Number of subjects: 11
Study 31512330 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation (PLA)
Number of subjects: 11
Study 31512330 — intervention group
Group type: EXPERIMENTAL
Intervention: Equal duration trial following creatine supplementation (ISO)
Number of subjects: 11
Study 28670677 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraurethral lidocaine gel 2% plus intraglandular injection of lidocaine 2% (Group A)
Number of subjects: 156
Study 28670677 — intervention group
Group type: COMPARATOR
Intervention: Intraurethral lidocaine gel 2% alone (Group B)
Number of subjects: 156
Study 25624309 — intervention group
Group type: EXPERIMENTAL
Intervention: WHISTLER-online
Number of subjects: 645
Study 25624309 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 645
Study 23021709 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) to the breast/chest wall and regional lymph nodes
Number of subjects: 32
Study 21735653 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 98
Study 21735653 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg once daily
Number of subjects: 98
Study 18155752 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet aggregometry (PA) using adenosine diphosphate (ADP) and arachidonic acid (AA)
Number of subjects: 404
Study 18155752 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact‐R (Cone and Plate(let) Analyzer technology)
Number of subjects: 404
Study 18155752 — intervention group
Group type: COMPARATOR
Intervention: Impact‐R compared to PA
Number of subjects: 404
Study 16615719 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-game players
Number of subjects: 97
Study 16615719 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilinguals
Number of subjects: 97
Study 16615719 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (no conflict)
Number of subjects: 97
Study 16615719 — intervention group
Group type: COMPARATOR
Intervention: Simon task with conflict
Number of subjects: 97
Study 12697573 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 10207
Study 12697573 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated)
Number of subjects: 10207
Study 10961749 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic placement of the catheter (Group B)
Number of subjects: 50
Study 10961749 — intervention group
Group type: COMPARATOR
Intervention: Open laparotomy technique (Group A)
Number of subjects: 50
Study 9175687 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive for anti-beta2GPI antibodies (group II)
Number of subjects: 510
Study 9175687 — intervention group
Group type: COMPARATOR
Intervention: Negative for both antibodies (group I)
Number of subjects: 510
Study 9175687 — intervention group
Group type: COMPARATOR
Intervention: Positive for aCL only (group III)
Number of subjects: 510
Study 1337164 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (3 x 10(6) units thrice weekly for the first 6 weeks, then twice weekly for a further 8 weeks)
Number of subjects: 74
Study 1337164 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 74
Study 1337164 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study 1337164 — intervention group
Group type: COMPARATOR
Intervention: Interferon and Control group
Number of subjects: 74
Study 3989143 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (0.25 and 0.50 nmol X kg‐1 X min‐1)
Number of subjects: 8
Study 3989143 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study 3989143 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (during allergen challenge)
Number of subjects: 8
Study 3989143 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (high dose)
Number of subjects: 8
Study 30180054 — intervention group
Group type: EXPERIMENTAL
Intervention: Local steroid (40 mg of local triamcinolone)
Number of subjects: 75
Study 30180054 — intervention group
Group type: EXPERIMENTAL
Intervention: IV steroid (10 mg of IV dexamethasone)
Number of subjects: 75
Study 30180054 — intervention group
Group type: COMPARATOR
Intervention: Control (no steroid)
Number of subjects: 75
Study 27491619 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-weeks high-intensity training (HIT)
Number of subjects: 18
Study 27491619 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-weeks high-intensity training (HIT)
Number of subjects: 18
Study 24193232 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR on floor
Number of subjects: 24
Study 24193232 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR on mattress
Number of subjects: 24
Study 24193232 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR on backboards
Number of subjects: 24
Study 24193232 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback device on floor
Number of subjects: 24
Study 24193232 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback device with second sensor on mattress
Number of subjects: 24
Study 22699134 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback condition (mirrors used)
Number of subjects: 25
Study 22699134 — intervention group
Group type: COMPARATOR
Intervention: Control condition (mirrors covered)
Number of subjects: 25
Study 20179689 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition chromocolonoscopy
Number of subjects: 660
Study 20179689 — intervention group
Group type: COMPARATOR
Intervention: High-definition white light colonoscopy
Number of subjects: 660
Study 19164187 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 750 microg twice daily
Number of subjects: 129
Study 19164187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 16120115 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical periodontal treatment combined with systemic doxycycline, 100 mg day(‐1) for 14 days
Number of subjects: 52
Study 16120115 — intervention group
Group type: COMPARATOR
Intervention: Neither periodontal treatment nor systemic doxycycline
Number of subjects: 52
Study 12107836 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m(2)) + Marimastat
Number of subjects: 239
Study 12107836 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m(2)) + Placebo
Number of subjects: 239
Study 10402383 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.06 mg/kg and Ketamine 0.75 mg/kg
Number of subjects: 50
Study 10402383 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 0.017 mg/kg, Propofol 2.5 mg/kg and Isoflurane
Number of subjects: 50
Study 7530597 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin (0.03 unit/ml for 5 hours)
Number of subjects: 153
Study 7530597 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 153
Study 2033221 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nasogastric antacid infusion at 0.5 ml/min and i.v. injection of cimetidine 100 mg/h (treatment group)
Number of subjects: 25
Study 2033221 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 50 mg 8 hourly i.v. (control group)
Number of subjects: 25
Study 7018363 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination tablet containing 5 mg of timolol, 25 mg of hydralazine, 25 mg of hydrochlorothiazide and 37.5 mg of triamterene
Number of subjects: 37
Study 7018363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 31464811 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant mental practice using inverse video of the unaffected limb for 20 minutes before every session of rehabilitation
Number of subjects: 20
Study 31464811 — intervention group
Group type: COMPARATOR
Intervention: Conventional occupational therapy alone
Number of subjects: 20
Study 28296348 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Brassica diet (6 portions of 84g broccoli, 6 portions of 84g cauliflower, 6 portions of 300g broccoli and sweet potato soup)
Number of subjects: 10
Study 28296348 — intervention group
Group type: COMPARATOR
Intervention: Low-Brassica diet (1 portion of 84g broccoli, 1 portion of 84g cauliflower)
Number of subjects: 10
Study 25279816 — intervention group
Group type: COMPARATOR
Intervention: Original guidance
Number of subjects: 0
Study 25279816 — intervention group
Group type: COMPARATOR
Intervention: Alternative guidance
Number of subjects: 0
Study 23292233 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (200 mcg twice daily)
Number of subjects: 77
Study 22145499 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib sodium injection (treatment group; n = 133)
Number of subjects: 268
Study 22145499 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group; n = 135)
Number of subjects: 268
Study 19307511 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy duration more than 5 years
Number of subjects: 189
Study 19307511 — intervention group
Group type: COMPARATOR
Intervention: Hormonal therapy duration less than or equal to 1 year
Number of subjects: 189
Study 19307511 — intervention group
Group type: COMPARATOR
Intervention: Hormonal therapy duration more than 1 year and less than or equal to 5 years
Number of subjects: 189
Study 15637558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal amphotericin B (20 mL, 250 mug/mL, twice daily for 6 months)
Number of subjects: 30
Study 15637558 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 mL, twice daily for 6 months)
Number of subjects: 30
Study 15637558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal amphotericin B
Number of subjects: 30
Study 15637558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11832528 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing (basic rate, 15 beats per minute faster than the mean nocturnal sinus rate)
Number of subjects: 15
Study 11832528 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing
Number of subjects: 15
Study 10076939 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose glucocorticoid (prednisone at < 5 mg/day) for at least 12 months
Number of subjects: 78
Study 10076939 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti‐rheumatic drugs (NSAIDs)
Number of subjects: 78
Study 7720339 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide infusion
Number of subjects: 9
Study 1817904 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication with a combination of a neuroleptic drug and an opiate or a benzodiazepine
Number of subjects: 83
Study 1817904 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 83
Study 1817904 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication
Number of subjects: 83
Study 7449717 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (10 mg)
Number of subjects: 21
Study 7449717 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam (10 mg)
Number of subjects: 21
Study 7449717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31863016 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive electrical stimulation at 0.5 Hz, 1.1 Hz, and 1.6 Hz with pulse width of 1 ms at the bladder dome or trigone
Number of subjects: 40
Study 31863016 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive electrical stimulation at 0.5 Hz
Number of subjects: 40
Study 31863016 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing stimulation
Number of subjects: 40
Study 27613814 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of ropivacaine for 24 hours
Number of subjects: 100
Study 27613814 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion for 24 hours
Number of subjects: 100
Study 25648969 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative glenohumeral injection of bupivacaine (20mL) and lidocaine (10mL)
Number of subjects: 121
Study 25648969 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative injection administered in the subacromial space of bupivacaine (20mL) and lidocaine (10mL)
Number of subjects: 121
Study 25648969 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of glenohumeral and subacromial injections of bupivacaine (20mL) and lidocaine (10mL)
Number of subjects: 121
Study 25648969 — intervention group
Group type: COMPARATOR
Intervention: Demerol as a postinjection rescue analgesic
Number of subjects: 121
Study 24307267 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC therapy
Number of subjects: 43
Study 24307267 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressing change
Number of subjects: 43
Study 21278378 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive distraction
Number of subjects: 61
Study 21278378 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive distraction
Number of subjects: 61
Study 21278378 — intervention group
Group type: COMPARATOR
Intervention: No distraction control
Number of subjects: 61
Study 19755697 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin alone
Number of subjects: 500
Study 19755697 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin only
Number of subjects: 500
Study 19755697 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus insulin
Number of subjects: 500
Study 19755697 — intervention group
Group type: COMPARATOR
Intervention: Placebo metformin
Number of subjects: 500
Study 19755697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 17530677 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary job retention vocational rehabilitation program
Number of subjects: 121
Study 17530677 — intervention group
Group type: COMPARATOR
Intervention: Usual outpatient care
Number of subjects: 121
Study 15300570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1519
Study 15300570 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin 81 mg/day
Number of subjects: 1519
Study 15300570 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg combined with aspirin 81 mg/day
Number of subjects: 1519
Study 15300570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg 3 times a day
Number of subjects: 1519
Study 11214056 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rhTFPI (0.05 mg/ml)
Number of subjects: 622
Study 11214056 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rhTFPI (0.15 mg/ml)
Number of subjects: 622
Study 11214056 — intervention group
Group type: COMPARATOR
Intervention: Heparin (100 U/ml)
Number of subjects: 622
Study 9881389 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraflo II equipment
Number of subjects: 30
Study 9881389 — intervention group
Group type: COMPARATOR
Intervention: Carmeda equipment
Number of subjects: 30
Study 9881389 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 8082100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (24 mg i.v.) in Study 1
Number of subjects: 346
Study 8082100 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (3 mg i.v.) in Study 1
Number of subjects: 346
Study 8082100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg orally twice a day) for delayed emesis in Study 1
Number of subjects: 346
Study 8082100 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (3 mg i.v.) for delayed emesis in Study 1
Number of subjects: 346
Study 8082100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (16 mg i.v.) in Study 2
Number of subjects: 346
Study 8082100 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (3 mg i.v.) in Study 2
Number of subjects: 346
Study 2644877 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg daily
Number of subjects: 22
Study 2644877 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 40 mg daily
Number of subjects: 22
Study 2644877 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (both doses)
Number of subjects: 22
Study 2644877 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 22
Study 1103213 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (30 to 240 mg of elemental iron as ferrous fumarate)
Number of subjects: 0
Study 1103213 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (120 mg of iron without B12 or folate)
Number of subjects: 0
Study 1103213 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (with vitamin B12 and folate)
Number of subjects: 0
Study 1103213 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 1103213 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 and folic acid alone
Number of subjects: 0
Study 1103213 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (120 mg or more)
Number of subjects: 0
Study 1103213 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 0
Study 31027912 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent practice with simulated mortality possible (n=12)
Number of subjects: 48
Study 31027912 — intervention group
Group type: COMPARATOR
Intervention: Independent practice without simulated mortality (n=12)
Number of subjects: 48
Study 31027912 — intervention group
Group type: COMPARATOR
Intervention: Support from attending physician with simulated mortality possible (n=12)
Number of subjects: 48